These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743 [TBL] [Abstract][Full Text] [Related]
9. Management of BCG failures in superficial bladder cancer: a review. Witjes JA Eur Urol; 2006 May; 49(5):790-7. PubMed ID: 16464532 [TBL] [Abstract][Full Text] [Related]
10. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951 [TBL] [Abstract][Full Text] [Related]
15. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564 [TBL] [Abstract][Full Text] [Related]
16. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? Herr HW; Sogani PC J Urol; 2001 Oct; 166(4):1296-9. PubMed ID: 11547061 [TBL] [Abstract][Full Text] [Related]
17. T1G3 bladder tumours: the case for conservative treatment. Turner W Eur Urol; 2004 Apr; 45(4):401-5. PubMed ID: 15041101 [No Abstract] [Full Text] [Related]